Serum Calprotectin Versus Acute-Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors.
about
Calprotectin in rheumatic diseases: a review.Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.Calprotectin (S100A8/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritis.Calprotectin in rheumatic diseases.Calprotectin as a Biomarker for Melioidosis Disease Progression and Management.Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study.Calprotectin (S100A8/A9) should preferably be measured in EDTA-plasma; results from a longitudinal study of patients with rheumatoid arthritis.Calprotectin levels in rheumatoid arthritis and their correlation with disease activity: a meta-analysis.Elevated calprotectin in patients with atrial fibrillation with and without heart failure.Equivalent Units of Serum C-Reactive Protein and Calprotectin are Compared in a Recent RA Study: Comment on the Article by Inciarte-Mundo et al.Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis.
P2860
Q34549912-912CB64D-7A36-4601-8C1A-9B5F6B97E889Q37080199-732DE92B-B8E6-4B2E-A3F9-92CE0D354F05Q37584844-25894DB1-D1D4-4880-8D1E-43125392CA04Q39022858-E8EB9BA2-EE8F-4696-8389-9C5A0DA3257DQ39295421-AD99A928-8F80-4836-BD74-70623FF87469Q41497288-001F2F9E-F25D-4C0D-9CCA-FE52F34E2F28Q47253535-F9CC07CA-B909-419B-B607-4290D6B7F3DEQ51046090-89752DC2-A08A-4F48-895E-C4FEBEC360BFQ51104775-A3FB2AF6-64EC-4887-80FB-E7EA3747935AQ51387336-BDD7FC03-4C8D-4899-9603-380B39D1390EQ55376762-66AC03AA-FED3-4DC3-84E0-78F3EA20D79C
P2860
Serum Calprotectin Versus Acute-Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Serum Calprotectin Versus Acut ...... or Necrosis Factor Inhibitors.
@en
Serum Calprotectin Versus Acut ...... or Necrosis Factor Inhibitors.
@nl
type
label
Serum Calprotectin Versus Acut ...... or Necrosis Factor Inhibitors.
@en
Serum Calprotectin Versus Acut ...... or Necrosis Factor Inhibitors.
@nl
prefLabel
Serum Calprotectin Versus Acut ...... or Necrosis Factor Inhibitors.
@en
Serum Calprotectin Versus Acut ...... or Necrosis Factor Inhibitors.
@nl
P2093
P2860
P50
P356
P1476
Serum Calprotectin Versus Acut ...... mor Necrosis Factor Inhibitors
@en
P2093
Andrea Cuervo
Jordi Yagüe
José Inciarte-Mundo
Julio Ramirez
Mariona Pascal
Sonia Raquel Cabrera-Villalba
P2860
P304
P356
10.1002/ACR.22795
P577
2016-07-01T00:00:00Z